DiNAQOR Introduces Breakthrough Platform for Precision Drug Delivery

DiNAQOR and its academic collaborators have unveiled a new platform for precise in vivo delivery of advanced therapies, as detailed in a study published in JACC: Basic to Translational Science. The technology utilizes a catheter-based closed-loop loco-regional perfusion (LRP) system, enabling high-precision organ-specific delivery, thus reducing systemic exposure risks associated with gene and cell therapies. This approach is expected to revolutionize kidney-targeted treatments, with the newly formed DiNATEQ AG facilitating clinical translation.

The LRP platform allows for targeted delivery, significantly enhancing local payload concentration and reducing off-target effects. Compatible with various therapeutic modalities, the system promises broader applicability across solid organs beyond just the kidney.

Mayo Clinic has acknowledged LRP as a breakthrough in precision therapy delivery, highlighting its potential to overcome existing delivery barriers and reduce systemic toxicity. This innovation is poised to transform gene, RNA, and regenerative medicine.